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Abstract 
Background: The US Army designed artelinate/lysine salt (AL) to overcome the instability of sodium artesunate in 
aqueous solution (AS). To select the most efficacious artemisinin treatment, direct comparison was performed in an 
uncomplicated non‑human primate malaria model.
Methods: Splenectomized rhesus monkeys were inoculated with Plasmodium coatneyi and on day six, single equi‑
molar loading dose of IV AL (11.8 mg kg−1) or IV AS (8 mg kg−1) were administered followed by 1/2 the first dose once 
daily for 2 more days. Blood smear were performed twice daily and the number of parasites were counted micro‑
scopically. Blood samples were obtained after the first dose within 6 h for pharmacokinetic (PK) and ex vivo pharma‑
codynamic evaluation by simultaneously measuring plasma drug concentration and anti‑malarial activity against 
Plasmodium falciparum in vitro.
Results: The anti‑P. coatneyi in vivo activity of both compounds were comparable, but the ex vivo anti‑P. falciparum 
potency of the IV AS regimen as administered was sevenfold higher than that of IV AL. Comparing in vivo pharmaco‑
dynamics of AL and AS, daily assessed parasite counts showed comparable 99 % parasite clearance times (PC99: 2.03, 
1.84 day), parasite clearance rates (5.34, 4.13 per min) and clearance half‑life (PCt1/2: 7.79, 10.1 h). This study showed 
strong and significant inverse correlation between PCt1/2 and t1/2 of AS + DHA, and AUC0–∞ of DHA, and correlated 
with Vz of AS (r
2 > 0.7, p ≤ 0.002). Lastly, following IV AL, there was a modest inverse correlation between PCt1/2 and 
Cmax (r
2 0.6, p ≤ 0.04). Although all tested monkeys recrudesced subsequently, two died following AL regimen before 
parasite clearance. While the aetiology of those deaths could not be definitively determined, pathologic evidence 
favoured a sepsis‑like syndrome and suggested that severe malaria was more likely than drug toxicity.
Conclusion: The model demonstrated that both AS and DHA contributed to the anti‑malarial activity of IV AS, while 
IV AL activity was largely restricted to the parent drug. Parasite clearance was strongly and linearly dependent on drug 
exposure for both artemisinin regimens. However, IV AS had higher ex vivo potency against P. falciparum, leading to 
an IND filing for GMP manufactured AS in the United States.
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Background
Despite reductions in morbidity and mortality, severe 
malaria still kills a half a million persons worldwide 
each year, including travelers [1]. Severe malaria occurs 
when Plasmodium infection is complicated by serious 
organ failure or metabolic abnormalities which develop 
rapidly and can progress to death within 24–48 h, and 
requires parenteral therapy. Since 1991, quinidine glu-
conate remains the only FDA-approved drug available 
for severe malaria infection in the US. It is available 
in limited supply, requires continuous infusion with a 
loading dose in an intensive care unit for cardiac and 
glycaemic monitoring, and resistance has been docu-
mented [2, 3]. Artesunate (AS) was developed and 
tested as a replacement for quinine. AS has now been 
receiving WHO-prequalification status since 2010 and 
adopted as the recommended treatment; but a Good 
Manufacture Practice (GMP) product remains inacces-
sible in many countries [4]. Intravenous AS was associ-
ated with a lower risk of hypoglycaemia and has been 
shown to significantly reduce the risk of death from 
severe malaria compared to IV quinine [5, 6]. Artesu-
nate is also a more practical option in resource-poor 
settings since administration is simpler (by bolus injec-
tion) and does not require slow rate-controlled infusion 
as well as cardiac monitoring [5, 7].
During the testing of parenteral artesunate, the US 
Army, through the Walter Reed Army Institute of 
Research, had considered developing another artemisinin 
derivative, artelinic acid-l-lysine salts (AL) and was 
patented in 1988 [8] as anti-malarial agents for clinical 
treatment of severe malaria. Artelinate, a semi-synthetic 
derivative of artemisinin, does not convert readily to 
dihydroartemisinin (DHA) was designed to overcome 
the instability of sodium artesunate in aqueous solution, 
which must be prepared at the bed side before injec-
tion. Pre-clinical efficacy and toxicity studies were used 
to select one of these artemisinin candidates as potential 
treatments for severe malaria and eventual FDA registra-
tion. Comparative anti-malarial efficacy of IV AL and AS 
in rat malaria model showed that AL had a superior anti-
malarial potency than AS in terms of parasitaemia clear-
ance [9]. However, this evidence also showed that AL was 
more toxic than AS in rats [10, 11].
Several non-human primate malaria models serve as 
useful surrogates to evaluate new drugs prior to test-
ing in humans. Plasmodium coatneyi is primate malaria 
that causes tertian malaria in splenectomized Asian 
macaques, complicated by sequestration of the infected 
erythrocytes and a high mortality rate in untreated ani-
mals [12]. This model most closely mimics severe and 
complicated malaria caused by Plasmodium falciparum 
[13, 14]. Limited efforts have used this model to study 
toxicity of drug due to brain-damage induced by lipid-
soluble depot artemisinins [13, 15]. The present study 
compared the pharmacokinetics and pharmacodynamics 
of AL and AS in the uncomplicated P. coatneyi infected 
rhesus monkey model to test the new candidate drugs for 
severe malaria treatment.
Methods
The United States Army Medical Component, Armed 
Forces Research Institute of Medical Sciences (USAMC-
AFRIMS) Institutional Animal care and Use Committee 
and the Animal Use Review Division, US Army Medical 
Research and Materiel Command reviewed and approved 
the protocol. Research was conducted in 2002 in compli-
ance with the Animal Welfare Act and other federal stat-
utes and regulations relating to animals and experiments 
involving animals and adheres to principles stated in the 
Guide for the Care and Use of Laboratory Animals, NRC 
Publication, 1996 edition. The USAMC-AFRIMS animal 
care and use programme has been accredited by Asso-
ciation for Assessment and Accreditation for Laboratory 
Animal Care International since 1999.
Plasmodium coatneyi‑Rhesus monkey model
Plasmodium coatneyi-infected RBCs (wild-type strain 
originally donated by W.E. Collins, CDC, Atlanta, GA) 
were maintained as cryopreserved stabilates at AFRIMS, 
Bangkok, Thailand. The stabilate stock was tested and 
confirmed negative for B-virus, SRV, SIV and STV-1 to 
ensure no adventitious viruses transmission were intro-
duced to the monkey colony. Twenty-two adult colony-
born, Indian-origin rhesus macaques (Macaca mulatta) 
naïve monkeys were splenectomized and recovered 
well more than 1 month prior to entering the study. All 
monkeys were free from B-virus, SIV, SRV and STLV 
antibodies. Animal health screening included complete 
physical examination, CBC, ALT and creatinine. Twenty-
two animals were randomized to two experiments of 11 
monkeys. Each experiment included ten experimental 
monkeys (IV AL and AS) and one control animal. The 
control monkeys received intramuscular quinine treat-
ment and the experimental animals received intravenous 
artemisinin candidates.
Keywords: Monkey malaria, Artelinic, Artelinate, Artesunate, Pharmacokinetics, Pharmacodynamics, Parasite 
clearance
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Infected donor monkey
For each experiment, after thawing a stabilate of P. 
coatneyi-infected erythrocytes, 1  ml aliquot was inocu-
lated intravenously to the test monkey. The monkey 
was sedated with ketamine HCl (5–15  mg  kg−1, IM) 
for this procedure. Parasitaemia levels were monitored 
daily. After the parasite density reached >50,000 para-
sites  µl−1, 5–20  ml of blood was drawn from a femoral 
vein into a heparinized tube. Blood was divided into 1 ml 
aliquots (about 5  ×  106 RBC with a 1  % parasitaemia) 
for inoculation of the study animals. Then, the donor 
animal was treated with chloroquine hydrochloride 
10 mg kg−1 day−1 IM for 5–7 days. This was the stand-
ard treatment regimen for P. coatneyi-infected control 
animals at AFRIMS based on local protocols. The inject-
able chloroquine hydrochloride (Aralen™ 40 mg base/ml) 
was given by intramuscular route. The injection has been 
practical since it can be given with minimal animal han-
dling using the “squeeze cage” mechanism. Animals were 
monitored daily and the treatment range of 5–7 days was 
used as the benchmark for when blood smear evaluation 
became negative.
Parasitaemia and clinical monitoring
Animals were observed at least twice daily to assess clini-
cal signs and correlates of severe malaria. Based on our 
previous model validation, blood smears were performed 
to detect malaria parasites starting prior to inocula-
tion on day 0 and continued daily (0700–0800  h). The 
monkeys were physically restrained in the squeeze cage 
restraint apparatus and approximately 0.1–0.2 ml whole 
blood was collected from each monkey by lancet punc-
ture of the lateral auricular vein. Thick and thin smears 
were made on the same microscope glass slide and sub-
sequently fixed in methanol and stained with Giemsa. 
When the smears were positive, white blood cell count 
(WBC) and/or red blood cell count (RBC) were also per-
formed using automated haematology analyzer Sysmex 
K800 to calculate parasite density. Haematocrits were 
checked as needed. At study days 6–12, additional blood 
samples were obtained from all animals in the afternoon 
(1500–1600  h) to monitor parasitaemia levels. Daily 
blood smears were continued until two consecutive days 
with negative smears. Then the smear monitoring sched-
ule was reduced to two times weekly for 2 weeks and then 
weekly for 6 weeks after completion of the last treatment. 
Treatment failures and/or recrudescence were treated 
with IM quinine dihydrochloride 60  mg  kg−1 loading 
dose, followed by 30 mg kg−1, every 8 h for 3 days.
Treatment was initiated at parasitaemias ≥3  % or 
>200,000 parasites  µl−1 (on study day 6 morning) due 
to rapid increasing in parasitaemia levels observed in 
previous model development and dose-ranging studies 
(unpublished data). Blood smear staining and parasitae-
mia determination took about 2 h. The first dose of treat-
ment was decided after the results were confirmed. The 
eleven monkeys were treated as one cohort when the 
majority met the treatment criteria and allowed for prac-
tical blood drawing and processing for PK sampling. The 
control monkey received quinine treatment and the ten 
experimental animals received intravenous artemisinin 
derivative candidate. Animals were pole-and-collar 
trained and sat in restraining chairs to receive the IV 
injection and phlebotomy without the use of chemical 
restraint to avoid potential confounding and depression 
by concomitant anesthetic administration.
Chemicals
Artelinic acid (WR255663), 4-(10′ dihyro-artemisinin-
oxymethyl) benzoic acid hemihydrate, was prepared as 
an l-lysine salt (MW 573.719) powder at Walter Reed 
Army Institute of Research (WRAIR; Silver Springs, 
MD) and shipped to AFRIMS through WRAIR Chemi-
cal Information. Artesunic acid (MW 384.425) and 5  % 
sodium bicarbonate solution was obtained from Guilin 
Pharmaceutical, Guangxi, China and imported by Atlan-
tic Pharmaceutical Co., Ltd., Bangkok, Thailand. Arteli-
nate/lysine salt (AL) powder prepared with 1 g of the acid 
content was equivalent to 1.35 g of the salt weight. Intra-
venous AL was prepared from a stock solution contain-
ing 40 mg L−1 of AL by dissolving the calculated amount 
of the AL salt in a solution of 0.45 % NaCl/0.1 % l-lysine 
(w/v), sterilized and filtered through 0.2 µm cellulose ace-
tate. Additional IV solutions with the required concen-
trations of AL was made by appropriate dilution of the 
40  mg  L−1 solution with normal (0.9  %) saline contain-
ing 0.1 % l-lysine, followed by filtration through a syringe 
filter prior to use. Intravenous artesunate/sodium salt 
(AS) was prepared by dissolving the acid in 5 % sodium 
bicarbonate just prior to injection per manufacturer 
instructions.
Dosing regimen
Single, equimolar doses 20 μmol of IV AL (11.8 mg kg−1) 
and IV AS (8  mg  kg−1) were administered as a rapid 
bolus injection over a 1-min period. These doses were 
chosen as the minimal effective doses (from previous 
model development and validation studies, unpublished 
data) and blood was collected for pharmacokinetic analy-
sis. After a week wash-out and recovery period, P. coat-
neyi (1 mL of >50,000 parasitized RBCs per microlitre or 
5 ×  106 RBC with a 1  % parasitaemia) were inoculated 
from a donor monkey into all the monkeys. The treat-
ment was initiated at day 6 after inoculation at a parasi-
taemia ≥3 % or >200,000 parasites μL−1 when the cohort 
of animals was minimally symptomatic. Drugs were given 
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for 3 days with a loading dose initially followed by ½ of 
the first dose on the 2nd and 3rd days. Consequently, 
each monkey served as its own control for intra-subject 
variation, and differences are likely due to the disease 
effects from malaria infection.
Blood collection and sample preparation
Blood was collected for pharmacokinetic/pharmacody-
namics (PK/PD) analysis after the first dose only due to 
rapid clearance of artemisinin derivatives. Heparinized 
blood was collected at 0, 5, 20, 40 min, 1, 3, and 6 h post-
dose and plasma samples were separated within 2  h by 
centrifugation (1500g, 10 min). Aliquots of samples were 
made for simultaneous measurement by HPLC [16] and 
bioassay [14], and stored at −80  °C until analysis. All 
glassware was silanized before use with a 0.5  % aque-
ous solution (v/v) of Pierce Aquasil (Rockford, IL, USA) 
according to the manufacturer’s recommended proce-
dure. Solid-phase extraction was performed on C-18 
elution cartridge (3.0  ml, J.T. Baker Co.) using a VAC 
ELUTE SPS24 sample processing station (Analytichem 
International, Harbour City, CA, USA). The cartridge 
was preconditioned by sequential washing with 2.5  ml 
acetonitrile, 2.5 ml methanol and 2.5 ml water. One ml of 
distilled water was added to the cartridge before adding 
plasma sample (0.5 ml). Then, the cartridge was washed 
with 2.5 ml distilled water, 2.5 ml of 0.05 % H3PO4 (pH 
4.5) and 2.5 ml of 20 % acetonitrile and completely dried 
by closing the vacuum for 15 min. The analytes were col-
lected by eluting with 0.5  ml methanol three times and 
then with 0.5  ml 90:10 n-butyl chloride: ethyl acetate 
twice. The organic phases were pooled. The combined 
organic phases were then evaporated to dryness under 
a stream of nitrogen at room temperature. Extraction 
residues were reconstituted with 50:50 ethanol: water 
(0.3 ml), at least 16 h before injection. The injection vol-
ume was 100 µl for all samples.
The plasma concentration of parent drugs, AL and AS, 
and their primary metabolites, DHA and 2-hydroxyarteli-
nate (OHAL) respectively, were measured by HPLC with 
electrochemical detection in reductive mode (HPLC-
ECD) [16], which was the only method for artemisinin 
compounds then (Additional files 1 and 2). The total anti-
malarial activity of the drug and all active metabolite(s) in 
plasma were measured by bioassay against in vitro P. fal-
ciparum clone (W2) and expressed as DHA equivalents 
[14] (Additional file 3).
Chromatography
HPLC with reductive electrochemical detection was 
performed using a model BAS 200B liquid chromatog-
raphy (Bioanalytical Systems, Inc., West Lafayette, Indi-
ana, USA). A Nova-Pak® C18 (3.9  ×  150  mm, Waters 
Corporation, Milford, MA, USA) was used with 40  % 
acetonitrile in sodium acetate buffer (pH 3.6) as mobile 
phase. Detection was performed using a thin dual-layer 
glassy carbon electrode run in parallel mode at a poten-
tial of −1.0 V versus Ag/AgCl. The system was operated 
at the following temperatures: mobile phase 35  °C, col-
umn and detector oven 30  °C, cell 31  °C with the flow 
rate of 1.5  mL  min−1. Artemisinin (ART) was used as 
an internal standard. Samples were injected via Gilson 
model 231 XL sampling injector equipped with a 100 µL 
loop, a Gilson model 401 dilutor/pipettor, a sampler con-
troller keypad (Gilson Medical Electronics, Middleton, 
WI, USA), and a Valco electrically actuated switching 
valve (Valco Instrument Co. Inc) was used. This system 
automatically deoxygenated and injected sample, which 
permits the high sample throughput associated with 
automated injection. Data were acquired and analysed 
using a Millennium32 Chromatography Manager (Waters 
Corporation, Milford, MA, USA).
Standard curve and quality control samples were pre-
pared by spiking plasma with 50:50 ethanol:water solu-
tions of AS with DHA or AL with OHAL. The final 
concentration range was from 10 to 2000  ng  mL−1 
plasma. Artemisinin 250 ng mL−1 was added as an inter-
nal standard to all samples.
Ex vivo Plasmodium falciparum‑based bioassay (BA)
The plasma anti-malarial activities of the artemisinin 
derivatives were measured using a previously published 
method [14]. In brief, plasma was incubated with pro-
tein A to remove the majority of immunoglobulin (IgG) 
that results in the lysis of the parasites in the erythro-
cytes (heat treatment was not used due to the effect on 
the stability of artemisinin derivatives in plasma). After 
centrifugation, the supernatant (100 µL) was transferred 
to a 96-well flat bottom plate. Twofold serial dilutions 
were then made using heat inactivated pooled control 
serum (human:rhesus  =  1:1). A suspension of malaria 
(W2 clone) infected erythrocytes was added to each well. 
The microtitre plate was placed into a gas-tight plexiglass 
chamber, flushed with a gas mixture of 90 % CO2, 5 % O2, 
and 5  % N2, and placed into an incubator (37  °C). Fol-
lowing 24 h incubation, the plate was removed from the 
chamber and pulsed with [3H]-hypoxanthine solution to 
each well and incubated for another 18–20 h before har-
vesting. The incorporation of [3H]-hypoxanthine by the 
parasites in each well was determined by counting in a 
scintillation counter.
A dose–response curve for each plasma sample was 
constructed by plotting [3H]-hypoxanthine uptake on 
the Y-axis against the corresponding dilution factor on 
the X-axis after logarithmic transformation. The dilution 
factor value that inhibits parasite growth by 50 % (DF50) 
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of each plasma sample was determined. Using the DF50 
value, the anti-malarial activity of the plasma sample was 
extrapolated from a linear standard curve using DHA, 
the most potent artemisinin derivative, and expressed as 
DHA equivalents.
Assessment of parasite counts
Blood smear were collected once daily in the morning. 
Once positive parasitaemia was observed and reached 
2000 parasites μL−1, blood smears were collected twice, 
in the morning and afternoon. Blood for slides prepa-
ration were collected from ear for thick and thin smear 
preparation. Blood films on glass slides were air dried, 
fixed with 100  % methanol, stained with Giemsa, and 
read under ×100 magnification oil emersion for parasite 
determination.
First, a thick smear was performed for parasite detec-
tion by reading the slides at least 50 fields under ×100 
magnification oil emersion. If no parasite was detected 
in all 50 fields, “negative” parasitaemia was reported. If 
on average five parasites were detected/field under ×100 
magnification oil emersion, the number of parasitized 
RBCs was counted per 100 WBC. This number was 
used for the number of parasites μL−1 of blood using the 
formula:
Blood CBC was determined by automated haematol-
ogy analyzer Sysmex K800 every other day. When para-
site density was greater than ten parasites/field, parasites 
were counted per 1000 RBC. Thin smear was used when 
number of parasite was greater than five parasites per 
field in thick film. For counting parasite density/RBC, a 
grid micrometre was used and the number of parasitized 
RBCs was used for calculation. If the parasite density was 
less than ten parasites μL−1 the determination of parasi-
taemia was counted per 100 WBC (calculation method of 
parasite number was the same as thick smear).
The percentage of infected RBC was determined by 
enumerating the number of infected RBCs in relation 
to the number of uninfected RBCs. One thousand RBCs 
were counted and calculated as follows:
The number of asexual parasites μL−1 of whole blood 
was determined by counting white blood cells (WBC) 
in high-power fields containing a total of 500 parasites 

















number of parasites per 1000 WBCs was counted if the 
ratio of parasites/WBC was less than one. The parasitae-
mia level was calculated as the product of the parasite/
WBC ratio and the WBC count (microscope filed that 
is well-populated with WBCs (20 WBCs/field) and five 
views were used for parasitaemia count).
In vivo pharmacodynamics (iPD) analysis
The parasite density-time curve was constructed and 
the parasite clearance parameters were estimated using 
Parasite Clearance Estimator [17]. The parameters were 
parasite clearance rate (PCR), clearance half-life (PCt½), 
PC50, PC95, PC99 (PCn—defined as the time from ini-
tiation of treatment to the time parasites were cleared by 
n  %). In addition, the parasite clearance time (PCT) by 
conventional method (defined as the time from initiation 
of treatment to the time the first two consecutive nega-
tive blood smears) was assessed by microscopy.
Pharmacokinetic analysis
Non-compartmental analysis was used to derive pharma-
cokinetic parameters of AS and its metabolite DHA, AL 
and its metabolite OHAL, using WinNonlin™ Standard 
Edition, v 2.1 (Pharsight Corporation, Cary, NC, USA). 
The PK parameters determined were the elimination 
rate constant (λz) was calculated by least-squares regres-
sion analysis of the ln-linear portion of the plasma con-
centration–time curve (the number of time points >3). 
The elimination half-life (t1/2) was calculated from the 
ratio of 0.693/λz, the maximum concentration (Cmax) in 
plasma and the time to reach Cmax after dosing (Tmax) 
were obtained by inspection, the area under the concen-
tration–time curve (from time zero to 20 min, AUC0–20, 
and zero to infinity, AUC0–∞) was estimated by the lin-
ear trapezoidal rule. The apparent total body clearance 
(Cl) and volume of distribution (Vz) associated with the 
terminal phase were calculated as dose/AUC, and Cl/λz, 
respectively.
Statistical analysis
Statistical comparison between dosage regimens was 
performed using the Mann–Whitney U test and all the 
values reported were in median with 25th and 75th inter-
quartile. The correlation between two variables was per-
formed using simple linear regression model with least 
square method. Results were considered statistically sig-
nificant when the p value was <0.05. (Prism 6 for Win-
dows v. 6.01)
Results
Clinical results and in vivo pharmacodynamics (iPD)
Monkeys in the two treatment groups had comparable age 
and weight (Table 1). The parasite density of each control 
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monkey receiving quinine were 773,550 and 510,260 para-
sites μL−1 for AL and AS group, respectively, which were 
within the range of the corresponding experimental mon-
keys. Parasite clearance-time profiles were shown in 
Fig. 1a–c (Additional file 4). Although animals treated with 
IV AL had statistically significant higher starting parasite 
density (727,850 vs 261,452; p 0.0005) and longer PC95 
(1.22 vs 0.85 days, p 0.01), there were not significantly dif-
ferent in the PC99 (2.03 vs 1.84 day, p 0.3), PCR (5.34 vs 
4.13 count.min−1, p 0.1), and PCt1/2 (7.79 vs 10.1 h, p 0.1). 
Both formulations cleared the parasites so rapidly (Fig. 1d) 
that there were not sufficient data points to determine 
PC50 for all animals, only 4 of 8 for IV AL and 3 of 10 
for IV AS with their corresponding PC50 values varying 
from 2.72–10.9 h and 0.32–5.88 h respectively. Unexpect-
edly after IV AL injection, there were two deaths in the 
infected animals within 2.5 h. The blood smear from both 
monkeys taken at time of death had comparable parasite 
densities of 1.2 × 106 parasites μL−1 with a percentage of 
parasitized red blood cells at 15 and 20 %. There was evi-
dence of malaria and hepatic centrilobular degeneration 
consistent with shock. Though no clear etiology of death 
was determined, the findings favoured a diagnosis of severe 
malaria over drug toxicity, particularly since these doses 
were well tolerated by the other animals in the experi-
ment. Six animals failed treatment because parasite counts 
never reached zero and PCT could be determined in only 
two animals at 4.0 and 5.3  days. In contrast, PCT could 
be determined in all monkeys in the IV AS group with 
a median of 7.0  days and IQR between 5.1 and 8.0  days. 
However, the two monkeys with the most rapid PCT 
occurred at 4.0 and 5.0 days. Median PCT of the remaining 
eight monkeys was 8.0 days with an IQR between 5.8 and 
8.3 days. There was no relationship between PCT and ini-
tial parasite density. Furthermore, the parasites in the mon-
keys treated with IV AL, on average, kept increasing on day 
4 after dosing while those treated with IV AS continued to 
decrease and cleared by 1  week post-treatment (Fig.  1c). 
However, parasites recrudesced in all monkeys at a median 
(range, n) of 13 (9–19, 10) days in the IV AS group and 6.5 
(6–7, 2) days in the IV AL group.
Pharmacokinetics (PK)
The concentration–time profiles for each drug, its 
metabolite and anti-malarial activities for each animal 
are shown in Fig. 2 with mean values and 95 % CI shown 
in Fig. 3. Comparison of PK profiles for IV AL and IV AS 
showed no major differences between pre-infection and 
malaria infected states (Additional files 5, 6, 7, and 8). As 
a result, the PK and effect kinetics of ex vivo anti-malarial 
activity profiles or ex  vivo pharmacodynamics (ePD) of 
the two IV candidates in infected monkeys were directly 
compared. All PK and ePD parameter estimates were 
derived from Fig. 2.
Table 1 The initial status of the monkeys and in vivo pharmacodynamics, parasites clearance values
a Mann Whitney test
b Geometric mean and 95 % confidence interval
c Conventional method
Parameters Unit Rx Median 25th IQT 75th IQT pa
Monkey age Year IV AL 8 8 10 1.0
IV AS 9 7 12
Monkey weight kg IV AL 8.4 6.7 9.0 0.8
IV AS 7.7 6.9 8.7
Parasite densityb Count mL−1 IV AL 727,850 639,946 848,916 <0.001
IV AS 261,452 139,771 489,064
Parasites/erythrocyte (PE) % IV AL 12.0 11.3 12.7 <0.001
IV AS 6.60 4.23 6.83
Parasites clearance rate (PCR) Count min−1 IV AL 5.34 4.32 6.54 0.1
IV AS 4.13 3.69 5.28
Parasites clearance half‑life (PCt1/2) Hr IV AL 7.79 6.36 9.63 0.1
IV AS 10.1 7.88 11.3
95 % Parasites clearance (PC95) Day IV AL 1.22 1.13 1.27 0.01
IV AS 0.847 0.557 1.03
99 % Parasites clearance (PC99) Day IV AL 2.03 1.89 2.08 0.3
IV AS 1.84 1.47 2.01
Parasites clearance (PCT)c Day IV AL None None None NA
IV AS 7.00 5.07 8.00
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Table 2 shows PK parameter estimates of IV AL com-
pared to IV AS. Almost all PK variables for IV AL were 
significantly greater than that of IV AS (p < 0.0001). For 
parent drug AL, Cmax was twofold (60.2 vs 28.2  μM), 
t1/2 was eightfold (28.2 vs 3.47  min), AUC0–∞ was 
13-fold (3706 vs 288 μM.min), and AUC0–20 was 3-fold 
(925 vs 288 μM min) greater than that of AS. With the 
exception of the percentage of AUC0–20 compared to 
total AUC (%AUC0–20), AL was 1/4 that of AS (24.6 
vs 97.0  %). Moreover, the clearance (Cl) and the vol-
ume of distribution (Vz) of AS was 13-fold (72.3 vs 
5.60 L kg−1 min−1) and 1.5-fold (0.397 vs 0.259 L kg−1) 
greater than that of AL. The primary metabolites of AL 
and AS detected were OHAL and DHA respectively. 
The half-life values of OHAL (42.2  min) and DHA 
(31.1 min) were 1.5 and 9.0 fold longer than their par-
ent drugs. In addition, the AUC0–∞ of OHAL was only 
0.33 of its parent AL while that of DHA was 1.58 fold 
greater than its parent AS.
Ex vivo pharmacodynamic (ePD)
The effect kinetic parameters of ex  vivo anti-malarial 
activity (measured by BA expressed as DHA equiva-
lents), or ePD parameters of IV AL compared to IV AS 
were shown in Table 3. The anti-malarial activity t1/2 val-
ues were essentially the same at 30 min. The AUC0–∞ was 
not significantly different between groups (426 μM.min 
for IV AL and 485 μM.min for IV AS). However, there 
were significant differences in both groups among the 
ePD parameters Cmax and AUC0–20 where C max, of IV 
AS (20.7  μM) was 2.7 times greater than that of IV AL 
(7.76 μM) and AUC0–20 of IV AS (242 μM.min) was two-
fold greater than IV AL (115 μM.min).
Figure 3 indicated that the anti-malarial activity of IV 
AS was contributed by both the parent drug AS and its 
active metabolite DHA until 20 min post-dose when the 
major compound in plasma transitioned to DHA. Parent 
drug AS was below the detection limit beyond 1 h post-
dose and DHA was detected at its highest level as early as 
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Fig. 1 Parasite density‑time profiles. Parasite density‑time profiles of all test monkeys receiving IV AL (blue), IV AS (pink) and control monkeys 
receiving IM QN (orange) with corresponding color coded arrows indicating dosing time: a IV AL 11.8 mg kg−1 showing eight test monkeys (light 
blue) and two monkeys that eventually died within 6 h after the first dose (dark blue) and b IV AS 8.0 mg kg−1, in log scale and linear scale in inset. c 
Mean + 95 % confidence bar in plasma of P. coatneyi infected rhesus monkeys (solid line) including quinine control (dotted line) for each treatment. 
d Percentage (mean ± 95 % CI) of parasite reduction after treatment






























































































Fig. 2 Spaghetti plots of drug concentration–time profiles. Spaghetti plots of IV AL 11.8 mg kg−1 (a–d) and IV AS 8.0 mg kg−1 (e–h) in plasma of 
P. coatneyi infected rhesus monkeys showing drug concentration–time profiles of parent drugs (AL, AS), their metabolites (OHAL, DHA), combined 
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Fig. 3 Mean drug concentration and anti—P. falciparum activity‑time profiles. Drug concentration–time profiles (PK) measured by HPLC‑ECD 
and anti‑malarial activities‑time profiles (ePD) simultaneously measured by ex vivo bioassay against P. falciparum W2 clone following equimolar 
20 µmol kg−1 dose of a IV AL 11.8 mg kg−1, n = 8 and b IV AS 8.0 mg kg−1, n = 10 [reproduced from Fig. 5c (14)] in plasma of P. coatneyi infected 
rhesus monkeys. Top panel showed the parent drugs, their metabolites, combined parent and its metabolite, and anti‑malarial activities of each 
parenteral regimen. Bottom panel showed direct comparison of c parent drugs (AL vs AS), d their metabolites (OHAL vs DHA), e combined par‑
ent + metabolite (AL + OHAL vs AS + DHA), and f their anti‑malarial activities (IV AL vs IV AS). Values are mean ± 95 % CI
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5 min post-dose. As a result, AUC0–20 was 97 % of AUC0–
∞ for AS and 53 % for combined AS + DHA (Tables 2, 
3). On the other hand, although OHAL metabolite was 
detected by HPLC-ECD, only AL was responsible for 
plasma anti-malarial activity (Fig.  3) and the AUC0–20 
compared to the corresponding AUC0–∞ for AL and 
AL + OHAL which were comparable at 24.6 and 21.4 % 
respectively (Tables  2, 3). Furthermore, no DHA was 
found in plasma from either healthy or infected monkeys 
treated with IV AL.
Based on testing against the W2 clone, the in  vitro 
potency of AS was comparable to DHA and was 4–5 
times greater than that of AL. Since AS and its metabo-
lite DHA contributed to the plasma anti-malarial activity, 
ex vivo potency was then determined from the AUC0–∞ 
ratio between ePD and PK of the combined parent and its 
metabolite (Table 3). Thus, the ex vivo potency of IV AS 
(0.643) was sevenfold greater than IV AL (0.088).
Pharmacokinetic/pharmacodynamic correlation analysis 
(least square regression)
PK/ePD
Of all the parameters estimated, there were very strong 
correlations between PK and ePD for both formula-
tions (Table  4). Only the parent drug AL had a linear 
relationship between the ePD parameters and t1/2 and 
AUC0–∞ (r2 > 0.95, p < 0.0001). In contrast, t1/2 of DHA 
and AUC0–∞ of AS + DHA for IV AS correlated linearly 
with ePD and to a smaller degree (r2  >  0.74, p  <  0.001 
and r2 > 0.85, p < 0.0002, respectively). As expected, the 
AUC0–20 values of the parent components of both IV 
preparations correlated well with ePD parameters (AL: r2 
0.75, p 0.005 and AS: r2 0.80, p 0.0004). Only the Cmax of 
AS, but not AL, strongly correlated with ePD parameters 
(r2 0.81, p 0.0004).
PK or ePD)/iPD
The concentration–time profiles (PK) of parent + metab-
olite and the parasite density-time profile (iPD) for both 
parenteral regimens were shown in Fig.  4. The PK and 
ePD parameters for IV AS significantly correlated with 
those of iPD; while only the ePD of IV AL showed sig-
nificant correlation with iPD (Table  5). For IV AS, all 
PK parameters estimated, Cmax, AUC0–∞, t1/2, Cl and 
Vz, were significantly correlated well with the estimated 
parasite clearance parameters—PCt1/2, PCR, and PCT. 
The PK of parent AS showed its Vz, Cmax and Cl corre-
lated well with PCt1/2 (r2 0.72, p 0.002), PCR (r2 0.60, p 
0.009) and PCT (r2 0.53, p 0.02), respectively. The PK of 
DHA showed that AUC0–∞ inversely and strongly cor-
related with PCt1/2 (r2 0.71, p 0.002) and PCT (r2 0.61, p 
0.008) and t1/2 correlated with PCR (r2 0.58, p 0.01). The 
PK of combined AS + DHA showed its t1/2 inversely and 
strongly correlated with PCt1/2 (r2 0.77, p < 0.001), Cmax 
correlated with PCR (r2 0.62, p 0.007), and AUC0–∞ 
inversely correlated with PCT (r2 0.60, p 0.009). Lastly, 
Table 2 Pharmacokinetics of intravenous artelinate and artesunate in plasma from P. coatneyi infected rhesus monkeys
a Mann Whitney Test
b Cmax maximum concentration of drug reached in plasma
c  t1/2 elimination half‑life
d AUC0–∞ area under the concentration–time curve from zero to infinity
e AUC0–20 area under the concentration–time curve from zero to 20 min
f Cl apparent total body clearance
g Vz volume of distribution
Pharmacokinetics Rx Parent compound (P) Metabolite (M) M/P % AUC0–20
Parameter Unit Median 25th IQT 75th IQT pa Median 25th IQT 75th IQT pa AUC0–∞
Cbmax mM IV AL 60.2 55.9 65.3 <0.0001 10.9 9.10 13.4 <0.0001 0.18
IV AS 28.2 24.3 38.0 7.23 6.52 7.41 0.26
tc1/2 min IV AL 28.2 25.8 35.4 <0.0001 42.2 33.2 47.6 0.02 1.50
IV AS 3.47 3.09 5.15 31.1 25.0 34.5 8.97
AUCd0–∞ mM min IV AL 3706 2845 4218 <0.0001 1260 944 1519 <0.0001 0.33
IV AS 288 260 399 453 415 494 1.58
AUCe0–20 mM min IV AL 925 849 1028 <0.0001 117 100 153 0.7 24.6
IV AS 288 253 394 116 107 122 97.0
Clf L kg−1 min−1 IV AL 5.60 4.85 7.88 <0.0001
IV AS 72.3 52.4 79.9
Vz
g L kg−1 IV AL 0.259 0.241 0.294 0.07
IV AS 0.397 0.311 0.507
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the effect kinetic (ePD) of IV AS revealed that Cl and 
AUC0–∞ correlated with PCt1/2 (r2 0.57, p 0.01) and PCR 
(r2 0.52, p 0.02), respectively. On the other hand for IV 
AL, only Cmax correlated with PCt1/2 and PCR (r2 0.61, p 
0.04). Correlation analysis for PCT was not possible due 
to limited data points (n = 2). Figure 5 show the best PK-
iPD with strong correlation (r2 > 0.7) for IV AS and ePD-
iPD for both regimens.
Discussion
While direct comparison of safety and efficacy were com-
plicated by experimental factors, IV AS proved to have 
superior potency and more rapid parasite clearance com-
pared to IV AL. Similar to prior studies in humans [15, 
18, 19], PK/PD relationships for AS in monkeys revealed 
that the parent drug AS was rapidly converted to DHA 
and undetectable as early as 1  h post-dose. Activity 
and metabolic conversion were rapid. While AS was at 
fourfold higher concentration at 5  min post dose, only 
DHA remained responsible for the observed anti-malar-
ial activity roughly 20 min post-dose when plasma con-
centrations of DHA far exceeded AS. The t1/2 of DHA was 
at least ninefold longer than AS. This is consistent with 
prior observations in healthy human studies attributing 
the effectiveness of AS in part to its rapid and extensive 
hydrolysis to DHA, achieving high initial drug levels [18].
Challenges inherent to the model limit experimental 
interpretation to some degree. The two experimental 
groups were inoculated and dosed separately rather than 
concurrently to allow sufficient time to adequately per-
form all procedures. Based on previous model develop-
ment, the number of P. coatneyi parasites was expected 
to increase rapidly on study day 6. Therefore, blood para-
sitaemia was not measured prior to treatment in order 
to limit overall blood draws. Animals in the IV AS group 
were dosed first and morning parasitaemia levels varied 
Table 3 Pharmacokinetic parameters based on  combined parent drug and  metabolite levels and  ex  vivo pharmacody-
namics (ePD)
a Concentration reported as DHA equivalents
b Mann Whitney Test
c Cmax maximum concentration of drug reached in plasma
d t1/2 elimination half‑life
e AUC0–∞ area under the concentration–time curve from zero to infinity
f AUC0–20 area under the concentration–time curve from zero to 20 min
g Cl apparent total body clearance
h Vz volume of distribution
Pharmacokinetics Rx Ex vivo pharmacodynamica Combined P + M Ex vivo potency % AUC0–20
Parameter Unit Median 25th IQT 75th IQT pb Median 25th IQT 75th IQT pb ePD/PK AS/AL AUC0–∞
Ccmax mM IV
AL
7.76 7.09 8.13 <0.001 64.6 62.7 68.5 <0.001 0.120
IV
AS
20.7 15.3 30.5 35.2 31.3 44.4 0.587 4.89
td1/2 min IV
AL
29.6 26.3 38.0 0.7 36.3 30.6 44.8 0.02 0.815
IV
AS
29.9 23.4 33.2 29.1 23.7 31.4 1.028 1.26
AUCe0–∞ mM min IV
AL
426 365 521 0.8 4911 3997 5827 <0.001 0.088
IV
AS
485 297 586 764 698 926 0.643 7.31
AUCf0–20 mM min IV
AL
115 109 121 <0.001 1051 1007 1107 <0.001 0.110 21.4
IV
AS
242 172 348 404 373 502 0.598 5.44 52.9
Clg L kg−1 min−1 IV
AL





h L kg−1 IV
AL
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between 0.5 and 10.1 %, while parasitaemia in IV AL ani-
mals was between 7.1 and 20.2 %, with roughly twofold 
higher median parasitaemia in the IV AL group (12  %) 
compared to IV AS (6.6 %) at initial dose. To some extent, 
this makes a meaningful in vivo PK/PD comparison diffi-
cult. Moreover, there were two deaths in the IV AL group 
limiting available data from those animals. Baseline para-
sitaemias in these animals (13.2 and 13.0 %) were compa-
rable to those of other animals. Both monkeys died when 
their parasite density reached 1.2 ×  106  parasites  μL−1. 
Parasitaemias were 15 and 20 % respectively at 1 h apart 
suggesting that malaria was at the very least a major con-
tributor to their demise. Although the aetiology of death 
could not be determined definitively, pathologic exami-
nation favored a systemic inflammatory syndrome con-
sistent with severe malaria over drug toxicity.
The P. coatneyi model requires splenectomy in order 
to ensure adequate parasite infection and determine effi-
cacy, and the results should be interpreted in light of this 
consideration. Normally, the spleen removes abnormal 
erythrocytes and intra-erythrocytic inclusions, includ-
ing dead parasites which are removed from erythro-
cytes without erythrocyte destruction by the spleen 
[20]. Infected RBCs may persist longer and likely delayed 
parasite clearance compared to what would have been 
Table 4 Correlation between PK and ePD
PK = a*ePD + b
PK‑ePD linear regression IV AL IV AS
Parameter Analyte a b r2 p a b rp p
Cmax                    (mM) Parent 1.04 7.45 0.807 <0.001
t1/2 (min) Parent 0.69 7.89 0.964 <0.001
Metabolite 0.72 9.09 0.743 0.001
AUC0–∞ (mM min) Parent 7.88 124 0.951 <0.001
Combined 1.12 265 0.847 <0.001
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Density: IV AL (n=8)
Density: IV AS (n=10)
Conc: AL+OHAL
Conc: AS+DHA
Fig. 4 Comparison of mean parasite density and drug concentra‑
tion–time profiles. Mean parasite density‑time (iPD, solid line) and 
concentration–time (PK, dotted line) profiles of combined par‑
ent + metabolite for both parenteral regimens
Table 5 Linear regression analyses between PK or ePD and iPD
PK = a ∗ iPD+ b, or ePD = a ∗ iPD+ b
Treatment Compound PK (ePD) Unit iPD Unit r2 p a b
IV AS AS Vz mL kg
−1 PCt1/2 h 0.724 0.002 48.5 −57.2
Cmax mM PCR min 0.596 0.009 4.83 8.45
Cl L kg−1 min−1 PCT Day 0.534 0.02 12.5 −12.2
DHA AUC0–∞ mM min PCt1/2 h 0.709 0.002 −32.0 767
AUC0–∞ mM min PCT Day 0.608 0.008 −48.9 780
t1/2 min PCR min 0.576 0.01 2.30 19.3
AS + DHA t1/2 min PCt1/2 h 0.772 0.0008 −1.30 40.6
Cmax mM PCR min 0.619 0.007 5.09 14.0
AUC0–∞ mM min PCT Day 0.596 0.009 −98.5 1487
BA Cl L kg−1 min−1 PCt1/2 h 0.571 0.01 5.69 −4.08
AUC0–∞ mM min PCR min 0.516 0.02 87.6 71.1
IV AL BA Cmax mM PCt1/2 h 0.615 0.04 0.447 11.0
Cmax mM PCR min 0.611 0.04 0.665 3.82
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observed in spleen-intact animals. In a tissue distribution 
study in rats, 1 h following IV administration of AS, high 
levels of AS were found in brain, fat, intestine and serum, 
with comparatively low levels in other tissues including 
liver, kidney, testicle, muscle, fat, heart, eye, spleen and 
lung [21]. Splenectomy was unlikely to have had a signifi-
cant effect on the PK parameters and metabolism of AS 
or AL given the short half-life of both drugs.
In light of these findings, the human-rhesus dose con-
version factor can be derived based on PK parameters.
Let AUC in human = HA, AUC in Rhesus = RA, dose in 




AUC per unit dose in human = HA/HD
AUC per unit dose in Rhesus = RA/RD
Human/Rhesus conversion factor based on AUC per unit dose = F
F = AUC per unit dose in human/AUC per unit dose in Rhesus
 
 
Since equal AUC for human and Rhesus is desired, 
Then, 
The ePD of IV AS in uncomplicated P. coatneyi-infected 
rhesus monkey (8  mg  kg−1 dose) can be directly com-
pared to that of patients with uncomplicated falciparum 
malaria (2 mg kg−1 dose) [22]. Using total drug exposure, 
AUC values in human vs rhesus (636 vs 476 µM min), the 
AUC per unit dose for human was 318 and that of rhesus 
was 59.5. Therefore, the approximate inter-species con-
version factor for human in relation to rhesus is 5.34.
From Eq. (2), if the human dose = 2 mg kg−1,
Rhesus equivalent dose = 5.34*2
=10.7 mg kg−1
Vice versa, if the Rhesus dose = 8 mg kg−1,
= HA/HD ∗ RD/RA
(1)F ∗HD ∗ RA = HA ∗ RD
HA = RA
(2)F = RD/HD
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c
Fig. 5 Pharmacokinetic‑pharmacodynamic correlation. The best three PK‑iPD correlations are shown in (a, b). All the PK parameters following IV 
AS treatment: t1/2 of AS + DHA (r2 0.772), the Vz of AS (r2 0.724), and AUC0–∞ of DHA (r2 0.709) showed strong and significant (p ≤ 0.002) correlation 
with the parasite clearance half‑life (PCt1/2). The ePD‑iPD correlation following both treatments is shown in (c). The PCt1/2 significantly (p ≤ 0.04) 
and inversely correlated well with the Cmax of the effect kinetics following IV AL (r
2 0.615) and correlated with the clearance (Cl) of the effect kinetics 
following IV AS (r2 0.570). Solid line denotes linear regression and dotted line denotes 95 % confidence interval
















































Human 636 318 Rhesus equi. 10.7
Rhesus 476 59.5 Human equi. 1.50
H/R 5.34
Values are mean (95 % Confidence interval)
Studies in multiple species [23, 24] have demonstrated 
limited conversion of AL to DHA. However, we found no 
DHA in rhesus plasma at all, instead detecting the OHAL 
metabolite by HPLC-ECD in accordance with a previous 
report suggesting that this is a product of rhesus monkey 
microsomes [25]. This finding indicates that the parent 
drug AL alone contributed to blood stage anti-malarial 
activity, and is concordant with earlier work also demon-
strating in vitro conversion of AL into OHAL in human 
liver microsomes [25, 26]. Furthermore, the effect of IV 
AS and IV AL on P. coatneyi recrudescence seen here in 
non-human primates was similar to that seen for Plasmo-
dium vinckei in rodents [27], suggesting the possibility 
that both AS and AL may trigger in  vivo parasites dor-
mancy in NHPs. This has been postulated as an under-
lying mechanism of treatment failure for artemisinin 
monotherapy [28]. Nevertheless, recrudescence due to 
short-course artemisinin treatment can be overcome by 
the use of combination therapy with slow acting anti-
malarial agents [29].
Correlation between drug exposure (PK) and drug 
effect (PD) for artemisinin compounds has been chal-
lenging due to rapid clearance of drug, unclear mecha-
nism of action, and sequestration in red blood cells 
combined with the inability to measure intraerythrocytic 
drug levels. Parasite clearance, a function of host-par-
asite-drug interactions, is a good measure of the in vivo 
drug effect. Davis et  al. [30] reported only a borderline 
significant inverse correlation between AUC and PC50 
following IV AS therapy for severe malaria in a 2001 
study. Ten years later, White [31] demonstrated that the 
parasite clearance time was associated with parasite den-
sity, potentially confounding PK/PD correlations with 
artemisinins, and this was borne out in subsequent field 
studies of oral artesunate monotherapy [32]. Bakshi et al. 
[33] developed a PK/PD in  vitro system and found that 
the efficacy of artemisinin depended on Cmax while that 
of chloroquine depended on its time above minimum 
inhibitory concentration, TMIC, which were confirmed 
in an in vivo Plasmodium berghei-mouse model. Pooled 
analysis of data from severe malaria patients following IV 
AS revealed there was no significant association between 
PCt1/2 and post hoc population PK estimates. Lastly, chil-
dren have been found to have lower DHA exposure than 
adults [34], with a recent study by Hawkes et al. [35] con-
cluding that slower parasite clearance in children rela-
tive to adults may be explained by lower DHA exposure. 
However, they did not observe any correlation between 
DHA exposure and parasite clearance.
In present study using uncomplicated P. coatneyi-
Rhesus monkey malaria model, PK-PD analysis of IV 
AS reveals an inverse linear correlation of DHA’s AUC 
with both PCt1/2 and PCT (Table  5) with longer PCt1/2 
and PCT resulting from lower DHA exposure. This is 
consistent with Hawkes’ conclusion in humans suggest-
ing that the rhesus model mimics human PK/PD for IV 
AS. Moreover, although AS is rapidly metabolized to 
DHA following IV administration, parasite clearance 
appears to be contributed by both components (Fig.  5) 
and the efficacy of IV AS depends on the t1/2 of combined 
AS + DHA > Vz of AS > AUC of DHA. In addition, IV 
AS had strong correlation between PK and iPD (in vivo 
drug effect against P. coatneyi-infected monkey) but 
not ePD (ex vivo drug effect against P. falciparum blood 
stage) and iPD suggesting that AS and DHA both con-
tributed to in vivo activity against both blood and tissue 
parasite stages. On the other hand effect kinetic param-
eter Cmax for IV AL was inversely correlated with PCt1/2. 
The strong correlation between PK and ePD as well as 
ePD and iPD implied that the in vivo activity of AL may 
be predominantly blood stage activity.
Conclusion
In a non-human primate model of uncomplicated 
malaria, IV AS had greater ex vivo potency against P. fal-
ciparum with higher anti-P. falciparum activity during 
the first 20 min of drug administration. The model dem-
onstrated that parasite clearance was dependent on drug 
exposure including both AUC and Cmax for both arte-
misinin regimens. While the efficacy of IV AS depended 
on the t1/2 of combined AS + DHA, the Vz of AS, and the 
AUC of DHA, efficacy of IV AL depended largely on its 
effect kinetic parameter Cmax, and was largely restricted 
to parent drug activity. As a result, IV AS was selected for 
further development for the treatment of severe malaria 
under an Investigational New Drug application (IND) 
held by the U.S. Army Office of the Surgeon General. 
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In the United States, it is currently available to patients 
under an IND treatment protocol maintained at the 
Centers for Disease Control [36] and by the military.
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